Watch Demo

KOL Perspectives: JAK Inhibitor Safety in IBD

KOL Perspectives: JAK Inhibitor Safety in IBD

  • Publish Date:May 2018

  • Number of Pages:31

  • Report ID:5588680

  • Format:PDF

  • Publisher:GlobalData

$ 2500

Summary

KOL Perspectives: JAK Inhibitor Safety in IBD

Summary
This KOL Insight briefing focuses on the potential use of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas -
- Maintenance data for selective JAKs in Crohn’s disease
- Differentiating strategies for selective and non-selective JAKs in IBD
- Choice of primary endpoints for IBD trials
- Selective JAKs’ expected efficacy in UC
- Real-world use of JAKs in IBD

Key Highlights
- KOLs are broadly positive about TOF’s safety profile in UC, highlighting TOF’s relative comparability to safety seen in other indications
- Most KOLs view the majority of JAK inhibitors in development in IBD as has having similar safety profiles, regardless of JAK-selectivity
- Most KOLs agree that patients should ideally be vaccinated before immunosuppressant treatment, however, reimbursement remains a significant barrier that can restrict vaccination to during treatment.

Scope
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our 10 key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 US-based
- Interviews performed during March 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma’s analysts.

Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "JAK Inhibitor Safety in IBD"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of contents

Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix

Companies Mentioned
- Pfizer
- Gilead
- Galapagos
- GSK
- AbbVie

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.